| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cobolimab | WBP 296A; TSR-022; GSK-4069889 | Phase 3 Clinical | Anaptysbio Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Diffuse Intrinsic Pontine Glioma; Ependymoma; Fibrolamellar hepatocellular carcinoma; Glioblastoma; Hepatoblastoma; Hodgkin Disease; Liver Neoplasms; Melanoma; Neoplasms; Osteosarcoma; Rhabdomyosarcoma; Uterine Cervical Neoplasms | Details |
| LB-1410 | LB-1410 | Phase 3 Clinical | L&L Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| Surzebiclimab | BGB-A425 | Phase 2 Clinical | BeOne Medicines Ltd | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Lomvastomig | RG-7769; RO-7121661; R07121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Melanoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| BMS-986258 | ONO-7807; BMS-986258 | Phase 2 Clinical | Bristol-Myers Squibb Company, Five Prime Therapeutics Inc | Neoplasms | Details |
| Sabatolimab | MBG-453; NVP-MBG453 | Phase 2 Clinical | Novartis Pharma Ag | Bone Marrow Diseases; Glioblastoma; Hematologic Diseases; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms; Polycythemia Vera; Preleukemia; Primary Myelofibrosis; Thrombocythemia, Essential | Details |
| Sabestomig | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| S-095018 | S095018; S-095018 | Phase 2 Clinical | Institut De Recherches Internationales Servier, Regeneron Pharmaceuticals Inc, Servier Bio-Innovation LLC | Carcinoma, Non-Small-Cell Lung | Details |
| Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University, Xuzhou Medical University (Xzmu) | Leukemia, Myeloid, Acute | Details | |
| TB-006 | TB-006; TB006 | Phase 2 Clinical | TrueBinding Inc | Alzheimer Disease; Autism Spectrum Disorder; Coronavirus Disease 2019 (COVID-19); Ischemic Stroke; Parkinson Disease | Details |
| BC-3402 | BC-3402; BC3402 | Phase 2 Clinical | Wuxi BioCity | Carcinoma, Hepatocellular; Hematologic Diseases; Hematologic Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Solid tumours | Details |
| TQB-2618 | TQB-2618 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Lymphoma; Melanoma; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| SHR-1702 | SHR-1702 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours | Details |
| LY-3321367 | LY-3321367 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours | Details |
| TIM-3 checkpoint inhibitor (Bristol-Myers Squibb) | Phase 1 Clinical | Five Prime Therapeutics Inc | Neoplasms | Details | |
| KL-A293 | KL-A293 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Neoplasms | Details |
| NB-002 (Suzhou Luosheng Bio-Pharmaceutical) | NB-002 (Suzhou Luosheng Bio-Pharmaceutical); NB-002 (逻晟生物); NB-002 | Phase 1 Clinical | NeoLogics Bioscience Co Ltd | Neoplasms; Solid tumours | Details |
| LPX-TI641 | LPX-TI-641 | Phase 1 Clinical | LAPIX Therapeutics Inc | Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Demyelinating Diseases; Dermatitis, Atopic; Multiple Sclerosis; Neuromyelitis Optica; Psoriasis | Details |
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | L&L Biopharma Co Ltd | Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| LBL-003 | LBL-003 | Phase 1 Clinical | Nanjing Leadsbiolabs Co Ltd | Neoplasms | Details |
| Sym-023 | Sym-023; Sym023; S95018 | Phase 1 Clinical | Symphogen A/S | Lymphoma; Neoplasm Metastasis; Solid tumours | Details |
| Verzistobart | INCAGN-02390; INCAGN-2390 | Phase 1 Clinical | Agenus Inc, Incyte Corp | Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Ovarian Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | Details |
| WBP-3425 | WBP-3425 | Phase 1 Clinical | Wuxi BioCity | Colonic Neoplasms; Solid tumours | Details |